<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04930224</url>
  </required_header>
  <id_info>
    <org_study_id>(Project no: 2019/5-24 M</org_study_id>
    <nct_id>NCT04930224</nct_id>
  </id_info>
  <brief_title>Serum GPER-1 and Oxidant/Antioxidant Levels on Retinopathy in Diabetic Patients</brief_title>
  <official_title>Comparing the Impact of Serum GPER-1 and Oxidant/Antioxidant Levels on Retinopathy in Diabetic Patients and Healthy Individuals: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kahramanmaras Sutcu Imam University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kahramanmaras Sutcu Imam University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational, comparative, cross-sectional study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was conducted on G protein-mediated estrogen receptor 1 (GPER-1), which is thought&#xD;
      to be effective in preventing the development of diabetic retinopathy (DR). There are studies&#xD;
      proving that GPER-1 prevents neuroprotective effects and vascular pathology in many tissues.&#xD;
      In the study, serum GPER-1 and oxidative stress biomarker levels were compared in diabetic&#xD;
      patients and healthy control groups. GPER-1 was found to be significantly increased in&#xD;
      diabetic patients. In addition, a positive correlation was found with oxidant markers. This&#xD;
      may lead to new treatment models in the future.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Actual">April 25, 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>G receptor-mediated protein-1 (GPER-1)</measure>
    <time_frame>Baseline</time_frame>
    <description>Variation of GPER-1 during the development of diabetic retinopathy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative/antioxidative stress markers (malondialdehyde [MDA])</measure>
    <time_frame>Baseline</time_frame>
    <description>Variation of oxidative/antioxidative stress markers during the development of diabetic retinopathy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative/antioxidative stress markers (catalase [CAT])</measure>
    <time_frame>Baseline</time_frame>
    <description>Variation of oxidative/antioxidative stress markers during the development of diabetic retinopathy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative/antioxidative stress markers (superoxide dismutase [SOD]</measure>
    <time_frame>Baseline</time_frame>
    <description>Variation of oxidative/antioxidative stress markers during the development of diabetic retinopathy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thyroid stimulating hormone (TSH)</measure>
    <time_frame>Baseline</time_frame>
    <description>Variation of TSH during the development of diabetic retinopathy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progesterone</measure>
    <time_frame>Baseline</time_frame>
    <description>Variation of progeterone during the development of diabetic retinopathy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>oestradiol</measure>
    <time_frame>Baseline</time_frame>
    <description>Variation of oestradiol during the development of diabetic retinopathy</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Hormones</condition>
  <arm_group>
    <arm_group_label>Proliferative Diabetic retinopathy</arm_group_label>
    <description>40 patients with proliferative diabetic retinopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Proliferative Diabetic retinopathy</arm_group_label>
    <description>40 patients with non-proliferative diabetic retinopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy individuals</arm_group_label>
    <description>40 healthy persons</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>The effect of GPER-1 on the formation of diabetic retinopathy</intervention_name>
    <description>Demonstrating the neuroprotective effect of GPER-1 in the formation of diabetic retinopathy and being a guide for new treatment models</description>
    <arm_group_label>Healthy individuals</arm_group_label>
    <arm_group_label>Non-Proliferative Diabetic retinopathy</arm_group_label>
    <arm_group_label>Proliferative Diabetic retinopathy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        People who applied to the tertiary eye outpatient clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  40 individuals were required to have Proliferative Diabetic Retinopathy (PDR);&#xD;
&#xD;
          -  40 were required to have Non-PDR;&#xD;
&#xD;
          -  40 were required to be healthy, without any systemic disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Glaucoma,&#xD;
&#xD;
          -  Ocular trauma sequelae,&#xD;
&#xD;
          -  Pathological myopia,&#xD;
&#xD;
          -  Non-diabetic retinopathy,&#xD;
&#xD;
          -  A history of previous ocular surgery,&#xD;
&#xD;
          -  Endocrine disorders (e.g.,thyroidopathy, adrenal gland disorders, pituitary&#xD;
             pathologies),&#xD;
&#xD;
          -  Opacities interfering with fundus examination (e.g., corneal opacity, lens opacity,&#xD;
             vitreous cloudiness other than diabetic haemorrhage).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdullah Beyoğlu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kahramanmaras Sutcu Imam University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abdullah Beyoğlu</name>
      <address>
        <city>Kahramanmaras</city>
        <state>None Selected</state>
        <zip>46040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kahramanmaras Sutcu Imam University</investigator_affiliation>
    <investigator_full_name>Abdullah Beyoğlu</investigator_full_name>
    <investigator_title>Assist of Prof</investigator_title>
  </responsible_party>
  <keyword>Diabetic retinopathy</keyword>
  <keyword>GPER-1</keyword>
  <keyword>oestradiol</keyword>
  <keyword>progesterone</keyword>
  <keyword>TSH</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>neuronal damage.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

